A new type of antibody drug conjugate targeting HER2 therapy for breast cancer:T-DM1 and T-DXd
Antibody drug conjugate is a promising class of drugs that utilize the specificity of monoclonal antibodies to selectively deliver the attached cytotoxic small molecules to the inside of tumor cells,achieving better results by increasing anti-tumor activity and decreasing off-target toxicity.With the advent of the era of precision tumor therapy,trastuzumab emtansine(T-DM1)and trastuzumab deruxtecan(T-DXd)have brought great hope for patients with human epidermal growth factor receptor 2 positive breast cancer,opening up a new phase in the treatment of HER2 overexpressing breast cancer and even some HER2 low-expressing breast cancer.This review discussed the mechanism of action,indication,efficacy and safety of T-DM1 and T-DXd,which may have an important guiding role for rational drug use.
T-DM1T-DXdantibody drug conjugateHER2breast cancer
NETL
NSTL
万方数据
